Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men who show no signs or symptoms, using a digital rectal examination, in which the prostate is manually assessed through the rectal wall, and measurement of prostate-specific antigen, or PSA, in the blood. Evidence remains insufficient to determine whether either screening tool reduces mortality from prostate cancer, and most recent guidelines recommend that the decision whether to screen be made through shared decision-making between patient and physician, informed of the risks and benefits; the American Society of Clinical Oncology has concluded it is uncertain whether the benefits of PSA testing are worth the harms of screening and any resulting unnecessary treatment.
Facts
Origin YearSourced to the subject's own account Connections
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Prostate_cancer_screening, lead sectionQuote, https://en.wikipedia.org/wiki/Prostate_cancer_screening, lead section
Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms.
2. Prostate-specific Antigen (Wikipedia)
WikipediaSerum levels section, first commercial PSA test paragraphQuote, Serum levels section, first commercial PSA test paragraph
The reference range of less than 4 ng/mL for the first commercial PSA test, the Hybritech Tandem-R PSA test released in February 1986, was based on a study that found 99% of 472 apparently healthy men had a total PSA level below 4 ng/mL.
Frequently Asked Questions
What was the first commercial PSA test?
The Hybritech Tandem-R test, released in February 1986.
The first commercial PSA test was the Hybritech Tandem-R PSA test, released in February 1986. Its reference range of less than 4 ng/mL was based on a study that found 99% of 472 apparently healthy men had a total PSA level below 4 ng/mL.
Does prostate cancer screening reduce deaths from the disease?
The evidence is insufficient to say; guidelines favor shared decision-making.
Evidence remains insufficient to determine whether either screening tool, the digital rectal examination or the PSA blood test, reduces mortality from prostate cancer. Most recent guidelines recommend that the decision whether to screen be made through shared decision-making between patient and physician, informed of the risks and benefits.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.